A Phase I/II trial is looking at combination of CXCR1/2 inhibitor AZD5069 with anti-PDL1 inhibitor durvalumab in patients with unresectable HCC who are treatment-naive or have progressed on no more than one line of therapy (ISRCTN12669009) [69]. The gene discussed is CD274; the disease is hepatocellular carcinoma.